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Introduction: Exhaled nitric oxide (FENO) is a reliable non-invasive marker of airway inflamma-
tion. In 2003 FENO chemiluminescence analyzer (NIOX
; Aerocrine AB, Solna, Sweden) was
approved by U.S. Food and Drug Administration for monitoring asthma therapy. Recently,
the same company developed a portable device using electrochemical sensors (NIOX-MINO;
Aerocrine AB). The aim of our study was to compare NIOX-MINO FENO values to those obtained
by NIOX and to calculate a correction equation.
Methods: Two adequate measurements obtained by NIOX and NIOX-MINO were recorded in
32 subjects (16 females, mean age 41 years).
Results: FENO values measured by NIOX-MINO
 were systematically higher than those obtained
by NIOX (47.1 ppb, IC 95% 35.2e59.1 and 36.9 ppb, IC 95% 25.0e49.0, respectively). There
was a significant correlation (rZ 0.998, p < 0.001) between FENO measured by the two
analyzers and the following conversion equation was calculated as:
FENO(NIOX)Z1.656(SEZ 0.61)þ 0.808(SEZ 0.009) FENO(NIOX-MINO)
Discussion: FENO values measured by the portable nitric oxide analyzer are reliable and
strongly correlated with values obtained by the standard stationary device, with a systematic
difference observed between the two instruments’ values that can be described by the conver-
sion equation we provided. This equation will help clinicians and researchers to compare data
obtainable by the two analyzers.
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Table 1 Demographic and clinical characteristics of
enrolled subjects
Total number, n 32
Asthmatics, n (%) 9 (28.1)
Atopics, n (%) 18 (56.2)
Current smokers, n (%) 5 (15.6)
Male/female ratio 1.0
Mean age, yrs (range) 41 (11e72)
Mean FENO, ppb (IC 95%, ppb)
NIOX 36.9 (25.0e49.0)
NIOX-MINO 47.1 (35.2e59.1)
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Exhaled nitric oxide (FENO) is a reliable non-invasive
marker of airway inflammation1 and it has been shown
to be elevated in several airway diseases such as
asthma,2 eosinophilic bronchitis,3 allergic rhinitis4 and
chronic rhinosinusitis.5 In the last 15 years, FENO emerged
as a potentially useful clinical tool being successfully
used to guide asthma treatment6 and demonstrating to
have an excellent negative predictive value for the diag-
nosis of asthma both in clinical settings4 and in epidemi-
ological studies.7
In 2003, a nitric oxide stationary chemiluminescence
analyzer (NIOX; Aerocrine AB, Solna, Sweden) was
approved by the U.S. Food and Drug Administration for
monitoring therapy in asthma.8 Recently, the same com-
pany has developed a new portable hand-held device using
electrochemical sensors (NIOX-MINO; Aerocrine AB, Solna,
Sweden) which could be an useful and easy device for the
everyday clinical practice.9
The hand-held device has been already validated for
measurement of FENO by Hemmingsson et al. in 2004.
9
Several data exist on the comparability of measurements
obtained by the two devices: some authors studied the
correlation between FENO measured by NIOX-MINO
 and the
stationary instrument in patients with asthma, both
adults10 and children,11 in patients with grass pollen
allergy,12 in children with respiratory symptoms,13 healthy
adults14 and in a heterogeneous population of adults and
children.15 All the authors found a strong correlation
between the measurements obtained with the two devices
(rZ 0.94e0.98). Many authors10,12e16 found higher FENO
values measured with NIOX-MINO compared with values
obtained with a stationary analyzer, the difference ranging
from 110 to 7.212 ppb. Three of these authors13e15 found
that FENO difference increased with increasing FENO level.
Hemmingsson et al.9 and Khalili et al.17 did not find any sig-
nificant difference between FENO measurements obtained
by NIOX-MINO and NIOX, while McGill et al. found that
FENO values were slightly lower for the NIOX-MINO
 com-
pared with the NIOX in children.11
The aim of our study was to compare FENO measured by
NIOX and NIOX-MINO, and to provide a correction equa-
tion between values obtained with the two devices.
Methods
Subjects
Thirty-two subjects (16 males, 18 atopics, 9 asthmatics,
and 14 non-atopic healthy controls) were included in the
study. The mean age was 41 years (range 11e72). Among
the 32 subjects, 5 (15.6%) were current smokers. Five of the
9 patients with asthma were receiving inhaled corticoste-
roids. The study was approved by local ethics committee
and all patients gave their informed consent.
Exhaled NO measurements
Fractional exhaled nitric oxide (FENO) has been measured
according to international recommendations.18 In detail,measurements obtained with NIOX were performed invit-
ing the subjects to inhale nitric oxide-free air through the
device and then to perform a 10-second exhalation at
a flow rate of 50 ml/s. Three technically adequate mea-
surements were performed with a sustained plateau of
10 s, and the mean was derived.
Measurements with NIOX-MINO were performed asking
the subjects to empty their lungs and then to inhale to total
lung capacity through the mouthpiece and finally exhale
into the device at a constant flow rate of 50 ml/s; the soft-
ware within the device automatically checks that the
breathing manoeuvre is performed according to ATS/ERS
recommendations.9,18
Two adequate measurements for each subject were
recorded both with NIOX and NIOX-MINO.
Statistical analysis
Statistical analysis was performed using package Stata vs.
10.0 (Stata Corp. LP, Texas, USA).
Demographic and clinical data were not considered
separately for statistical analysis, assuming that within-
subject differences were affected only by device, FENO
levels and random variation. BoxeCox analysis19 was used
to find the maximum likelihood estimates of the parameters.
The within-subject measurement variability was calcu-
lated for the two devices and reported as coefficient of
variation.
The relationship between measurements was estimated
with linear least square regression with bootstrap estima-
tion. Conversion equation was obtained from estimated
points.20
Results
All the recruited subjects were able to perform acceptable
measurements with both devices.
The demographic and clinical characteristics of the
subjects are shown in Table 1.
The mean within-subjects standard deviation was 2.56
and 1.89 ppb and the mean within-subjects coefficient of
variation was 6.1 and 8.5% for NIOX-MINO and NIOX,
respectively.
Mean FENO values were 36.9 ppb (IC 95% 25.0e49.0 ppb)
and 47.1 ppb (IC 95% 35.2e59.1) with NIOX and NIOX-
MINO, respectively (Fig. 1).
FENO values measured by NIOX-MINO
 were systemati-
cally higher than those obtained by NIOX. The difference
Figure 1 Mean exhaled nitric oxide (FENO) measured by
NIOX and NIOX-MINO.
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with the increase of FENO values.
Gender, age, asthma or atopy did not affect the
relationship between the measurements obtained by the
two devices. There was a statistically significant correlation
(rZ 0.998, p< 0.001) between the values measured by the
two analyzers with a determination coefficient (R2) equal
to 0.996 (Fig. 2).
An equation to convert FENO values measured by NIOX-
MINO into those obtained by NIOX was estimated:
FENOðNIOXÞ[ 1:656ðSE[0:61Þ þ 0:808ðSE[0:009Þ
 FENOðNIOX-MINOÞ
The CI 95% of the calculated constant was2.9 to0.37,
suggesting that 0.81 could be the approximate correction
factor to convert NIOX-MINO into NIOX FENO values.
Discussion
In this study, the performance of a new hand-held device
for FENO measurement (NIOX-MINO
 - Aerocrine, Solna,
Sweden) has been compared with that of the standardFigure 2 Linear robust regression analysis (with CI 95%)
between NIOX and NIOX-MINO.stationary instrument (NIOX - Aerocrine, Solna, Sweden).
The portable device, for its manageability and easiness of
use, could be suitable for home-monitoring of asthma as
well as for epidemiological studies in the field.
The results of our study showed that FENO values mea-
sured by the portable nitric oxide analyzer are reliable
and strongly correlated with values obtained by the stan-
dard stationary device.
In agreement with most of the reported data10,12e16 FENO
values measured by the portable device have been found
higher than those obtained by the stationary instrument.
In literature, only one report11 showed that FENO values
measured by NIOX-MINO were slightly lower compared
with those obtained by NIOX: this results, however, were
probably affected by a faulty valve of the NIOX-MINO
device, as reported by the authors themselves.
The difference between values obtained by the two
instruments was found to increase with increasing FENO
values, as previously reported.13e15 According to this find-
ing, the absence of mean intrasubject FENO difference
between NIOX and NIOX-MINO reported by Hemmingsson
et al.9 could be related to the relatively low mean FENO
value (about 18 ppb) of the healthy subjects sample.
The systematic difference observed between the values
obtained by the two instruments implies the risk of classify-
ing as increased FENO values which are still in the normal
range when measured by the stationary device. Obviously
the problemmay be overcome by obtaining reference values
for the portable device. The simple conversion equation we
calculatedmay assist in the interpretation of the FENO values
obtained by NIOX-MINO. Assuming 25 ppb as the upper limit
of normal FENO values for NIOX
 as previously reported,21,22
the calculated upper limit of normal FENO values for NIOX-
MINO should be approximately 33 ppb.
Our data have been obtained by using the same calibra-
tion gas (200 ppb) for NIOX and the same electrochemical
sensor for NIOX-MINO. We cannot exclude that the use of
a different electrochemical sensor may change the relation-
ship between the measurements obtained by the two ana-
lyzers. The influence of the NIOX calibration on this
relationship should be negligible of NIOX, provided that
the recommended calibration gas (200 20 ppb) is used.
In conclusion, the novelty of this study is that a correc-
tion equation to convert FENO measured by NIOX-MINO
 into
those measured by NIOX has been provided, allowing to
compare data obtainable with the stationary instruments
with those measured during home-monitoring of asthma.
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